Literature DB >> 8807669

A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15.

C Sachse1, J Brockmöller, S Bauer, T Reum, I Roots.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8807669     DOI： 10.1097/00008571-199606000-00012

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  4 in total

1.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

Authors:  C Sachse; J Brockmöller; S Bauer; I Roots
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

2.  CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.

Authors:  S McElroy; C Sachse; J Brockmoller; J Richmond; M Lira; D Friedman; I Roots; B M Silber; P M Milos
Journal:  AAPS PharmSci       Date:  2000

Review 3.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

4.  CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.

Authors:  Amanda K Riffel; Mehdi Dehghani; Toinette Hartshorne; Kristen C Floyd; J Steven Leeder; Kevin P Rosenblatt; Andrea Gaedigk
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.